---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-182838"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-06-27T23:59:59+00:00"
generated_at: "2026-06-24T23:00:56.742407+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology closes $275M sale of Cullinan Pearl to Taiho; co-development deal for CLN-081

## Summary
- Upfront cash payment of $275M from Taiho; potential $130M in regulatory milestones for CLN-081/TAS6417.
- Taiho obtains exclusive global rights outside U.S.; companies co-develop and co-commercialize CLN-081 in U.S.
- U.S. profits and development costs split 50/50 between Cullinan and Taiho; Cullinan retains co-commercialization option.
- Deal includes sale of Cullinan Pearl Corp., which holds ex-Japan rights to CLN-081/TAS6417.

## SEC filing metadata
- accession: 0001193125-22-182838
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-06-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/0001193125-22-182838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522182838/d278047d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-182838
- JSON: https://secwatch.observer/filing/0001193125-22-182838.json
- Plain text: https://secwatch.observer/filing/0001193125-22-182838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.